About this document
Alectinib vs Crizotinib in ALK+ NSCLC by kalyan.niper44 is a document available to read on EtoBox.
The ALESIA study is a phase 3 randomized trial comparing alectinib and crizotinib as first-line treatments for ALK-positive non-small-cell lung cancer in Asian patients. Results showed that alectinib significantly prolonged progression-free survival and had a higher objective response rate compared to crizotinib, with fewer adverse events. This study supports the efficacy and safety of alectinib at a dose of 600 mg twice daily, aligning with previous global findings.
- Author
- kalyan.niper44
- Language
- EN